Brief

"On March 7, 2025, the Therapeutic Goods Administration (TGA) issued an update regarding Potential risk of neurodevelopmental disorders in children born to men taking sodium valproate. A retrospective observational study suggested an increased risk of neurodevelopmental disorders in children born to men treated with sodium valproate compared to those treated with lamotrigine or levetiracetam, prompting new warnings and precautions for health professionals and male patients."

This content is restricted.

Highlights content goes here...

This content is restricted.

Therapeutic Goods Administration (TGA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies